Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Middle East Conflict Impacts Australia and New Zealand Businesses 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
DURHAM, N.C., May 02, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 8:40 a.m. ET at the InterContinental Boston Hotel.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
